Neurology

Overview

Many neurological conditions are driven by the immune system or by an abnormal protein, and some of the medicines used to manage them are given by IV infusion or by injection under the skin. Infuse Care gives neurologist-prescribed infusion and injection therapies in private suites, with nurses who monitor each treatment and send updates back to your neurology team.

Conditions We Support

• Multiple sclerosis (relapsing forms, and primary progressive MS for Ocrevus)
• Generalized myasthenia gravis in adults with qualifying antibodies
• Chronic inflammatory demyelinating polyneuropathy (CIDP)
• Neuromyelitis optica spectrum disorder (NMOSD) in adults who are AQP4 antibody-positive
• Migraine prevention in adults
• Early Alzheimer's disease (mild cognitive impairment or mild dementia) with confirmed amyloid
• Polyneuropathy caused by hereditary transthyretin amyloidosis (hATTR) in adults
• Painful diabetic peripheral neuropathy of the feet in adults

Therapies That May Be Available at Infuse Care

• Ocrevus, Briumvi, Tysabri and Tyruko (MS): IV infusion
• Vyvgart and Ultomiris (myasthenia gravis): IV infusion
• Rystiggo (myasthenia gravis): subcutaneous infusion under the skin with a pump
• IVIG (CIDP): IV infusion; Vyvgart Hytrulo (CIDP): injection under the skin
• Soliris and Uplizna (AQP4-positive NMOSD): IV infusion
• Vyepti (migraine prevention): IV infusion every three months
• Leqembi and Kisunla (early Alzheimer's disease): IV infusion
• Onpattro (hATTR polyneuropathy): IV infusion; Amvuttra: injection under the skin
• Qutenza (diabetic peripheral neuropathy of the feet): a prescription patch applied to the skin in the office, not an infusion or injection

Whether a therapy is right for you, and how often it is given, depends on your diagnosis, test results and your neurologist's order.

How Treatment May Help

Depending on the condition, these medicines may help lower the risk of relapses or attacks, slow the progression of nerve damage or disability, reduce how often migraines occur, ease nerve pain, or slow clinical decline in early Alzheimer's disease. None of them is a cure, and results vary from person to person.

Treatment Considerations

Several neurology therapies carry important safety warnings. Soliris and Ultomiris raise the risk of serious meningococcal infections and require vaccination before treatment. Tysabri and Tyruko are linked to a rare brain infection called PML. Leqembi and Kisunla require MRI monitoring for brain swelling or bleeding (ARIA). Infusion and injection reactions can occur with many of these medicines. Our clinical team reviews each referral for safety requirements before scheduling, monitors you during and after each visit, and keeps your neurologist informed.